Part 13Additional relief for expenditure on research and development
Chapter 7F7Relief for large companies: vaccine research etc
Introductory
1085Overview of Chapter
1
This Chapter provides for relief for expenditure incurred by F1large companies on research and development relating to vaccine or medicine research.
2
Section 1086 defines “qualifying R&D activity” (that is, the research and development in relation to which relief under this Chapter is available).
F23
The relief available is a deduction under section 1087 (the amount of which is determined under section 1091).
F34
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F65
Sections 1098 to 1102 contain provision about when a company's expenditure is “qualifying Chapter 7 expenditure” for the purposes of obtaining relief and when such expenditure is “for” an accounting period.
F46
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7
Section 1112 contains an anti-avoidance provision dealing with artificially inflated claims for relief F5... under this Chapter.
8
See also section 1137 for provision about the accounting periods of a company which is not within the charge to corporation tax.
Pt. 13 Ch. 7 heading substituted (with effect in accordance with Sch. 3 para. 38 of the amending Act) by Finance Act 2012 (c. 14), Sch. 3 para. 30